INDIANAPOLIS — A potent anti-tumor gene introduced into mice with metastatic melanoma has resulted in permanent immune reconfiguration and produced a complete remission of their cancer, according to an article to be published in the December 2…
Prior research had found an association between DNA sequence variations in a gene that encodes parts of the brain’s gamma-amino butyric acid (GABA)-A receptors (the GABRA2 gene) and alcohol dependence.
New research has found that the GABRA2 g…
INDIANAPOLIS — Cost but not convenience plays a significant role in attitudes about vaccination for common human papillomaviruses for women over the age of 26, according to the authors of a recent article in the journal Sexual Health.
Currently, …
A medication used to treat the symptoms of mild-to-moderate Alzheimer disease may actually do more – it may be able to delay progression of the disorder, according to a study conducted at the Indiana University School of Medicine. The study, which appears in the June issue of Archives of Neurology, enabled researchers to evaluate a change in cognition observed in patients who prematurely discontinued treatment with placebo or Exelon ? (rivastigmine tartrate), a medication prescribed for many patients.
A new non-invasive therapy for liver cancer patients who cannot be helped by surgery or organ transplantation is being evaluated by researchers at the Indiana University School of Medicine. The Phase I clinical trial at the IU Cancer Center uses extracranial stereotactic radioablation (SRA) as a potential new treatment for hepatocelluar carcinoma, a cancer that originates in the liver, or for liver metastasis from other sites.
New research into the origin of kidney stone formation published in the March 1 issue of the Journal of Clinical Investigation may well change the direction of the most basic level of research in that area. The study will dispel the current beliefs of where stone formation begins, said the article’s lead author, adding that the research confirmed instead a hypothesis published in 1940 by Alexander Randall, M.D.
A compound developed by British scientists early in World War II as a treatment against chemical weapons has value against today’s threat of bioterrorism, according to Indiana University School of Medicine researchers at Indiana University-Purdue University Fort Wayne. Researchers studying British Anti-Lewisite provide an overview of its historical uses, development and clinical implications today of the heavy metal chelating agent, detailed in the March issue of the Annals of Emergency Medicine. BAL is a medical therapy to remove metal poisonings from the body.